If your institution subscribes to this resource, and you don't have an Access Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.
Download the Access App here: iOS and Android. Learn more here!
Lumoxiti17,155-157,#
CD22-directed antibody-cytotoxin conjugate (elongation factor 2 inhibitor)
Inotuzumab ozogamicina (CD22-directed calicheamicin cytotoxin); tagraxofusp-erzs (CD123-directed diphtheria toxoid elongation factor 2 inhibitor)
Hairy cell leukemia†
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Monoclonal Antibody–Cytotoxin Conjugates; > Chimeric Antigen Receptor T Cells
eChapter 2018 Part 2: The Goodman & Gilman Year in Review: 2018 New and Noteworthy FDA Approvals